Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher?
April 20, 2018, 11:30:00 AM EDT By Zacks Equity Research, Zacks.com
Shutterstock photo
As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. EYPT. The stock has moved higher by 40% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider EYPT's recent earnings estimate revision activity. From this look, the company's future is quite favorable; as EYPT has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. You can see the complete list of today's Zacks #1 Rank stocks here.
PVA Price at posting:
$2.80 Sentiment: Hold Disclosure: Held